Goni Katz-Greenberg

Living-donor kidney transplant (LDKT) and preemptive KT have emerged as superior treatments for end-stage kidney disease (ESKD), with outcomes that surpass both deceased-donor KT (DDKT) after dialysis and dialysis alone.

Keywords CMV, solid organ transplant, kidney transplantation, immunosuppression, prophylaxis Abstract Cytomegalovirus (CMV) infection poses a significant threat to solid organ transplant (SOT) recipients and can lead to various complications and adverse outcomes. In an effort to prevent CMV infection, it is common to utilize prophylactic strategies, including antiviral medications such as valganciclovir, especially for high-risk patients.